奇沃佐F的总合成方法
Tobias Brodmann1, Dominic Janssen, Markus Kalesse
1Centre for Biomolecular Drug Research (BMWZ), Leibniz Universität Hannover, Schneiderberg 1b, D-30167 Hannover, Germany.
Journal of the American Chemical Society
|September 15, 2010
概括
研究人员报告说,他们首次合成了生物活跃的奇沃佐F.这种新的方法利用了分子内静止合,克服了巨乳素形成的挑战,并证实了该分子的拟议结构.
科学领域:
- 有机化学 有机化学
- 自然产品的合成自然产品的合成
背景情况:
- 奇沃佐F是一种高度生物活性的天然产品.
- 以前的结构确定依赖于NMR,计算方法和遗传分析.
- 由于异构化,合成含有聚的巨乳素存在挑战.
研究的目的:
- 为了实现第一个chivosazole F.F.的全合成.
- 开发一种合成策略,避免四烯片段的异构化.
- 通过化学合成来证实奇沃佐F的拟议结构.
主要方法:
- 内部分子静止合用于巨乳素形成.
- 多步骤的有机合成途径.
- 用于结构确认的光谱和分析技术.
主要成果:
- 成功合成了奇沃佐 F.
- 这种分子内部的Stille合有效地形成了巨乳素.
- 合成途径绕过了烯部分存在问题的异构化.
- 合成验证了之前提出的结构.
结论:
- 完成了第一个Chivosazole F的总合成.
- 内部分子静止合是构建复杂的巨乳素的一个可行的策略.
- 合成为奇沃佐F.F.提供了明确的结构证明.
相关概念视频
Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Production of Biopesticides
Biopesticides offer a sustainable alternative to chemical pesticides, utilizing microbial agents to control agricultural pests. Bacillus thuringiensis (Bt) is a widely employed bacterium known for its potent insecticidal activity. Bt biopesticides are favored for their specificity to insect pests, minimal environmental impact, and natural degradability.Mechanism of Bt Toxin Action Bt produces insecticidal crystal (Cry) proteins during its sporulation phase. These proteins form parasporal...


